Cigna Group (CI) Projected to Release Quarterly Earnings on Thursday

Cigna Group (NYSE:CI) is expected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Cigna Group to post earnings of $7.52 per share and revenue of $72.64 billion for the quarter. Investors can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Cigna Group Trading Up 0.0%

Cigna Group stock opened at $295.21 on Wednesday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 0.76 and a current ratio of 0.76. The stock has a market cap of $78.01 billion, a PE ratio of 9.38, a price-to-earnings-growth ratio of 1.00 and a beta of 0.25. The stock has a 50-day moving average of $284.53 and a two-hundred day moving average of $281.77. Cigna Group has a one year low of $255.53 and a one year high of $316.27.

Cigna Group Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 17th. Stockholders of record on Thursday, December 3rd will be paid a dividend of $1.56 per share. The ex-dividend date is Thursday, December 3rd. This represents a $6.24 dividend on an annualized basis and a dividend yield of 2.1%. Cigna Group’s payout ratio is presently 25.82%.

Insider Transactions at Cigna Group

In related news, insider Nicole Jones sold 2,677 shares of Cigna Group stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $279.61, for a total transaction of $748,515.97. Following the completion of the sale, the insider owned 25,880 shares of the company’s stock, valued at $7,236,306.80. The trade was a 9.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Everett Neville sold 617 shares of the company’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $284.05, for a total value of $175,258.85. Following the completion of the sale, the insider owned 5,053 shares in the company, valued at approximately $1,435,304.65. This represents a 10.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on CI shares. Barclays upped their price objective on shares of Cigna Group from $304.00 to $310.00 and gave the company an “equal weight” rating in a report on Friday, July 31st. Jefferies Financial Group cut shares of Cigna Group from a “buy” rating to a “hold” rating and lowered their target price for the stock from $336.00 to $307.00 in a research note on Tuesday, August 4th. UBS Group reissued a “buy” rating on shares of Cigna Group in a research report on Thursday, October 1st. Sanford C. Bernstein restated an “outperform” rating on shares of Cigna Group in a research note on Friday, October 2nd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Cigna Group in a research note on Thursday, August 27th. Fourteen analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $336.40.

Cigna Group Company Profile

The Cigna Group (NYSE: CI) is a global health services company that provides insurance coverage, health care benefits and related services. Its operations are primarily organized through Cigna Healthcare, which offers medical, pharmacy, dental, behavioral health and other benefit programs to employers, government organizations and individuals, primarily in the United States.

The company also operates Evernorth Health Services, a health services platform that includes pharmacy benefit management, specialty pharmacy, care management and health-care delivery capabilities.